Britain and America have agreed to a landmark commercial pact that will keep no levies on UK drug products entering the US market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to raise funding on medicines through the NHS. This move guarantees that tariffs on these crucial goods will remain at nothing for a period of the next three years.
This development is in response to recent warnings to hike import taxes on patented drug imports, with increases floated reaching double the cost.
"This arrangement with the Britain bolsters the worldwide climate for innovative medicines and establishes long-overdue equity to U.S.–U.K. pharmaceutical trade," a statement said.
Commercial Significance
Drugs represent one of the the United Kingdom's biggest export categories to the US, which is easily the largest destination for major British pharmaceutical firms.
Trade data show that in the year leading up to the third quarter, the UK sold drugs totaling billions to the US. This amount represented a significant portion of all goods exports in that timeframe.
"This agreement secures work, increases funding and sets the stage for the UK to become a global hub for medical research," the Business and Trade Secretary stated.
Key UK Commitments
The deal includes several key pledges from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a target to double overall public funding on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum manufacturers must refund to the NHS to stay within budget will be restricted at 15%. Previously, repayments topped 20%.
Broader Context
This agreement takes place against a long-running tension between the sector and the British authorities over medicine costs and regulatory access.
These tensions were heightened by claims that US patients were paying a premium for the identical medicines than people in the Britain and the EU.
Recently, several large drug company projects in the UK have been delayed or abandoned, while major investments have been directed toward US facilities.
A senior figure acknowledged that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had shrunk as a percentage of its total funding over the previous ten-year period.
